Cooper Companies(NASDAQ) COO

Cooper makes contact lenses for people with vision problems. It also sells tools for women's healthcare and fertility clinics. These products help doctors and patients every day.

Helping People See Clearly

• Toric and multifocal: Soft lenses correcting complex vision issues like astigmatism and presbyopia; produced $364.9 million in net sales in Q2 2026.
• Spherical and other: Standard lenses for vision correction and myopia management; generated $358.6 million in net sales in Q2 2026.
• Office and surgical: Medical devices for obstetricians and gynecologists; provided $214.2 million in net sales in Q2 2026.
• Fertility services: Consumables and genetic testing for fertility clinics; accounted for $143.8 million in net sales in Q2 2026.

Strategic Shifts and Recalls

• Sauflon Group: Acquired in 2014, resulting in a long-term payroll tax dispute that remains under appeal as of June 2026.
• PNC Bank: Modified terms of major credit agreements in February 2026 to extend the maturity of $950 million in term loans.
• September 2025: Increased the share repurchase authorization to $2 billion to support the return of capital to stockholders.
• December 2023: Initiated a voluntary recall of specific LifeGlobal embryo culture media lots following reports of reduced embryo viability.

Global Presence and Specialized Care

Cooper maintains a strong international presence with manufacturing and marketing sites in the Americas, Europe, and Asia. The company focuses on unique vision products like MiSight, the first FDA-approved lens to slow childhood myopia.

Recent Financial Performance

• Revenue reached $1.1 billion in Q2 2026, up 7.9% year-over-year.
• Operating income fell to a loss of $31 million in Q2 2026, worsened by 116.8% from the previous year.
• Net income reached a loss of $77.9 million in Q2 2026, worsened by 188.8% year-over-year.
• Free cash flow hit a loss of $149.9 million in Q2 2026, worsened by 928.2% from Q2 2025.

Bottom Line

Cooper has evolved from a contact lens maker into a diversified healthcare business. Recent legal costs and product recalls have created significant financial hurdles while core sales categories continue to grow.